Access
To read this story in full you will need to login or make a payment (see right).
Correspondence
Nature 416, 677 (18 April 2002) | doi:10.1038/416677d
Open Innovation Challenges
-
Single-cell Analysis Platform
This Challenge is looking for novel approaches to analyzing changes at a single-cell level. This is...
-
Methods of Modeling Adaptation in Populations
The analysis of adaptation with a population is a frequently encountered computational modeling scen...
- More Challenges
- Powered by:
nature jobs
Tenure Professor for Bone and Skeleton Research
- Westfalian Wilhelms-University Munster, Germany
- Munster Germany
Head, Medical Writing
- Cactus Global
- Mumbai 400053 India
Call for Elan to publish Alzheimer's trial details
Glenda M. Bishop1, Stephen R. Robinson2, Mark A. Smith1, George Perry1 & Craig S. Atwood1
- Institute of Pathology, Case Western Reserve University, Cleveland, Ohio 44106, USA
- School of Psychology, Psychiatry and Psychological Medicine, Monash University, Clayton, Victoria 3800, Australia
One potential route for therapy for Alzheimer's disease involves the immunization of patients against the amyloid-
peptide, the major proteinaceous component that characterizes plaques in the brains of patients with this disease. Resulting from earlier research on mice, published in Nature1, 2, 3, Elan Pharmaceuticals recently began clinical trials of a vaccine, AN-1792, based on this approach.
To read this story in full you will need to login or make a payment (see right).
